The new MimixTM GeniTM reference standards were developed from the extensively tested Genome-in-a-Bottle Consortium (GIAB) cell line
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
The offering is expected to close on November 10, 2025, subject to customary closing conditions
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Subscribe To Our Newsletter & Stay Updated
